Research programme: oral hBNP - Biocon

Drug Profile

Research programme: oral hBNP - Biocon

Alternative Names: BN-054; BNP 054; NBN 002; NBN 054; NBN 054 - Biocon

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Biocon
  • Class Natriuretic peptides
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders
  • Discontinued Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in India (PO)
  • 26 Sep 2005 Data presented at the 9th Annual Scientific Meeting of the Heart Failure Society of America (HFSA-2005) have been added to the Heart failure pharmacodynamics section
  • 30 Aug 2005 Nobex and Biocon have entered into an agreement to co-develop oral hBNP worldwide for for the treatment of heart failure and other portential cardiovascular disease indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top